Patents Assigned to Merck
  • THIADIAZOLOPYRIDINE POLYMERS, THEIR SYNTHESIS AND THEIR USE
    Publication number: 20180105637
    Abstract: The present invention relates to thiadiazolopyridine polymers, their synthesis and their use. The present invention further relates to organic electronic devices comprising such thiadiazolopyridine polymers.
    Type: Application
    Filed: April 27, 2016
    Publication date: April 19, 2018
    Applicant: MERCK PATENT GMBH
    Inventors: William MITCHELL, Mansoor D'LAVARI
  • Nargenicin compounds and uses thereof as antibacterial agents
    Patent number: 9944654
    Abstract: The present invention relates to novel nargenicin related compounds which can inhibit DnaE and have antibacterial, particularly antimycobacterial activity against Mycobacterium tuberculosis. The present invention also relates to method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis by administering an antimycobacterially effective amount of nargenicin or a nargenicin-related compound and/or their pharmaceutically acceptable salts.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: April 17, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Katherine Young, David B. Olsen, Sheo B. Singh, Jing Su, Robert R. Wilkening, James M. Apgar, Dongfang Meng, Dann Parker, Mihir Mandal, Lihu Yang, Ronald E. Painter, Qun Dang, Takao Suzuki
  • Filling device and use thereof for dispensing a fluid
    Patent number: 9944416
    Abstract: The invention relates to a filling device (1) for dispensing a fluid into at least one container, where the filling device (1) has a weighing system (2) and a filling-needle system (3). The weighing system (2) has a positioning device (4) which can be adapted to a container diameter and which may have an annular design. The weighing system (2) is arranged on an accommodation platform (7) which can be moved vertically by means of a linear unit. The filling-needle system (3) is arranged on a displacement unit in a position at a distance in the axial direction above the positioning device (4).
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: April 17, 2018
    Assignee: Merck Patent GmbH
    Inventors: Guenter Hauke, Holger Jost, Leticia Garcia Diez, Michael Ukelis, Guenter Brenner
  • Factor XIa inhibitors
    Patent number: 9944643
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: April 17, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Santhosh F. Neelamkavil, Scott D. Edmondson, Alan W. Hruza, Zahid Hussain, Charles Lesburg, Remond Moningka
  • Materials for organic electroluminescent devices
    Patent number: 9947874
    Abstract: The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: April 17, 2018
    Assignee: Merck Patent GmbH
    Inventors: Christof Pflumm, Amir Hossain Parham, Constanze Brocke, Elvira Montenegro, Frank Voges, Holger Heil, Arne Buesing
  • Inhibitors of IRAK4 activity
    Patent number: 9943516
    Abstract: The present invention relates to inhibitors of IRAK4 of Formula I and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: April 17, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brian M. Andresen, Jason D. Brubaker, Anthony Donofrio, Thierry Fischmann, Craig R. Gibeau, Charles A. Lesburg, Jongwon Lim, John K. F. Maclean, Umar F. Mansoor, Alan B. Northrup, John M. Sanders, Graham F. Smith, Luis Torres
  • Process for preparing substituted pentacenes
    Patent number: 9944663
    Abstract: The invention relates to a process of preparing substituted pentacenes, to novel pentacenes prepared by this process, to the use of the novel pentacenes as semiconductors or charge transport materials in optical, electrooptical or electronic devices including field effect transistors (FETs), electroluminescent, photovoltaic and sensor devices, and to FETs and other semiconducting components or materials comprising the novel pentacenes.
    Type: Grant
    Filed: August 14, 2012
    Date of Patent: April 17, 2018
    Assignee: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Steven Tierney, Martin Heeney, Clare Bailey, Weimin Zhang
  • Microspheres
    Patent number: 9944778
    Abstract: The present invention relates to microspheres and to their use, preferably as laser absorbing additive, and to a process for their production.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: April 17, 2018
    Assignee: Merck Patent GmbH
    Inventors: Franciscus Wilhelmus Maria Gelissen, Franciscus Gerardus Henricus Van Duijnhoven
  • FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS
    Publication number: 20180099967
    Abstract: The present invention relates to Fused Tricyclic Heterocyclic Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising at least one Fused Tricyclic Heterocyclic Compound, and methods of using the Fused Tricyclic Heterocyclic Compounds for treating or preventing HIV infection in a subject.
    Type: Application
    Filed: December 13, 2017
    Publication date: April 12, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Tao Yu, Sherman T. Waddell, Thomas H. Graham, Yonglian Zhang, John A. McCauley, Andrew W. Stamford, Jiaqiang Cai, Zhiqi Qi
  • 3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRIDIN-2-ONE DERIVATIVES
    Publication number: 20180099947
    Abstract: Compounds of the formula I in which W, R1, R2 and R3 have the meanings indicated in claim 1, are inhibitors of ALK1, AL2 and ALK5, and can be employed for the treatment of diseases such as cancer.
    Type: Application
    Filed: March 22, 2016
    Publication date: April 12, 2018
    Applicant: MERCK PATENT GMBH
    Inventors: Dieter DORSCH, Alfred JONCZYK, Mireille KRIER
  • LIQUID CRYSTALLINE MEDIUM
    Publication number: 20180100104
    Abstract: The present invention relates to liquid-crystalline media (LC media), characterised in that they comprise one or more compounds of the formula I, and one or more compounds of the formula II, where the parameters have the meaning indicated in claim 1, to the use thereof in electro-optical displays, and to LC displays which contain these LC media.
    Type: Application
    Filed: March 3, 2016
    Publication date: April 12, 2018
    Applicant: MERCK PATENT GMBH
    Inventors: Mark GOEBEL, Rocco FORTTE, Lars LIETZAU, Christian HOCK
  • Purine inhibitors of human phosphatidylinositol 3-kinase delta
    Patent number: 9938281
    Abstract: The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: April 10, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Abdelghani Abe Achab, Michael D. Altman, Yongqi Deng, Solomon Kattar, Jason D. Katz, Joey L. Methot, Hua Zhou, Meredeth McGowan, Matthew P. Christopher, Yudith Garcia, Neville John Anthony, Francesc Xavier Fradera Llinas, Liping Yang, Changwei Mu, Xiaona Wang, Feng Shi, Baijun Ye, Sixing Zhang, Xiaoli Zhao, Rong Zhang, Kin Chiu Fong, Xiansheng Leng
  • Glycosidase inhibitors and uses thereof
    Patent number: 9938299
    Abstract: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: April 10, 2018
    Assignees: ALECTOS THERAPEUTICS, INC., MERCK SHARP & DOHME CORP.
    Inventors: Harold G. Selnick, Kun Liu, Ernest J. McEachern, Ramesh Kaul, Zhongyong Wei, Yaode Wang, Jiang Chang
  • C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
    Patent number: 9938268
    Abstract: Disclosed are C-ring modified tricyclic benzonaphthiridinone compounds and analogs thereof, pharmaceutical compositions comprising such compounds and processes for preparing the same. The compounds are useful in the treatment of diseases amenable to protein kinase signal transduction inhibition, regulation and/or modulation.
    Type: Grant
    Filed: December 2, 2009
    Date of Patent: April 10, 2018
    Assignee: Merck Patent GmbH
    Inventors: Yufang Xiao, Bayard R. Huck, Amanda E. Sutton, Thomas E. Richardson, Srinivasa R. Karra
  • Benzamides
    Patent number: 9938262
    Abstract: Novel benzamide derivatives of formula (I) wherein W1, W2, R1 to R7, R6, X and Y have the meaning according to the claims, are positive allosteric modulators of the FSH receptor, and can be employed, inter alia, for the treatment of fertility disorders.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: April 10, 2018
    Assignee: Merck Patent GmbH
    Inventors: Henry Yu, Andreas Goutopoulos, Thomas E. Richardson, Jiezhen Li, Brian H. Heasley, Pandi Bharathi
  • Liquid-crystalline media, components for high-frequency technology, and mesogenic compounds
    Patent number: 9938462
    Abstract: The present invention relates to a liquid-crystal medium which comprises a component A which consists of one or more compounds selected from the group of the formulae I-M and I-U in which the parameters have the respective meanings given in the claims or in the text, and to the corresponding, novel mesogenic compounds and to the preparation thereof. The present invention likewise relates to the use of these liquid-crystal media, in particular in components for high-frequency technology, and to components of this type which contain media according to the invention, and to the production and use of these components. The components according to the invention are suitable, in particular, as phase shifters in the microwave and millimeter wave region, for microwave and millimeter wave array antennae and very particularly for so-called tuneable “reflectarrays”.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: April 10, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Atsutaka Manabe, Dagmar Klass, Renate Seeger, Michael Wittek, Matthias Bremer
  • Method for vacuum purification
    Patent number: 9937438
    Abstract: The present invention relates to a process for the vacuum purification of chemical compounds and to an apparatus for carrying out this process.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: April 10, 2018
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stoessel, Juergen Fuchs
  • Liquid crystal medium and liquid crystal display
    Patent number: 9938464
    Abstract: The instant invention relates to mesogenic media comprising one or more compounds of formula G wherein the parameters are as specified in the text, preferably to mesogenic media showing a blue phase, preferably stabilised by a polymer, and their use in electro-optical light modulation elements and their respective use in displays, as well as to such devices.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: April 10, 2018
    Assignee: Merck Patent GmbH
    Inventors: Michael Wittek, Matthias Bremer, Erdal Durmaz
  • Oral pharmaceutical formulation of omarigliptin
    Patent number: 9937153
    Abstract: The present invention is directed to stable, oral pharmaceutical formulations of dipeptidyl peptidase-4 inhibitors, such as omarigliptin. Such pharmaceutical formulations comprise omarigliptin; and neutral excipients, wherein the neutral excipient is present in the amount of at least 75% by weight of the pharmaceutical formulation and comprises at least one non-reducible sugar diluent or a mixture of non-reducible sugar diluents.
    Type: Grant
    Filed: August 25, 2014
    Date of Patent: April 10, 2018
    Assignees: Merck Sharp & Dohme LTD., Merck Sharp & Dohme Corp.
    Inventors: Vincent Brett Cooper, Kathryn Alanna Bradley, Samuel Robert Pygall, Rajan Gupta, Madison Paige Stanford, Lin Xie
  • 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
    Patent number: 9938276
    Abstract: The present invention is directed to 6,5-bicyclic octahydropyrrolopyridine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: April 10, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ronald M. Kim, Scott D. Kuduk, Nigel Liverton, Gang Zhou